期刊
PLACENTA
卷 106, 期 -, 页码 30-39出版社
W B SAUNDERS CO LTD
DOI: 10.1016/j.placenta.2021.02.002
关键词
Preeclampsia; ELABELA; Syncytiotrophoblast; Placenta; Apoptosis
资金
- National Key R&D Program of China [2018YFC1004402]
ELABELA was found to have decreased expression in severe preeclampsia, while promoting trophoblast proliferation. It also showed potential in improving symptoms in a preeclampsia mouse model.
Introduction: Preeclampsia (PE) is associated with increased syncytiotmphoblast apoptosis. ELABELA (ELA) is a circulating hormone secreted by the placenta. Here, we investigated the involvement of ELA in the pathogenesis of PE. Methods: We measured ELA expression in the placental villi of patients with severe PE and healthy controls. A cellular model of hypoxia and reoxygenation was used to simulate PE hypoxia, and changes in the proliferation and apoptosis of trophoblasts in response to different ELA concentrations were measured. In addition, we used NG-nitro-L-arginine methyl ester (L-NAME) to generate a mouse model of pregnancy-induced hypertension and explore whether ELA can improve the symptoms of PE. Results: ELA expression was decreased in severe PE. ELA promoted the proliferation of BeWo cells and improved the decreased cell proliferation rate after hypoxia/reoxygenation injury. ELA reversed the phenotypes of L-NAME-induced PE mice and regulated the expression of mouse placental apoptosis factors. Discussion: ELA reduced apoptosis in BeWo cells and improved PE-like symptoms in mice, suggesting its value as a potential novel treatment for PE.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据